Autosomal Dominant Polycystic Kidney Disease (ADPKD
Nephrology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IpsenLanreotide
Clinical Trials (1)
Total enrollment: 159 patients across 1 trials
Lanreotide In Polycystic Kidney Disease Study
Start: Sep 2014Est. completion: Jul 2019159 patients
Phase 3Completed
Related Jobs in Nephrology
Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery
AstraZeneca
Sweden - Gothenburg
1w ago
Associate Director – Nephrology Market Access Strategy
Biogen
Cambridge, MA
1w ago
$164K - $226K/yr
Director, Strategy & Operations-Nephrology Franchise
Biogen
Cambridge, MA
1w ago
$195K - $269K/yr
Medical Science Liaison, CardioRenal - Portland, OR
AstraZeneca
Portland - OR, US
1w ago
Vice President, Head of Renal Sales
Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr
Specialty Account Manager, Nephrology- South Houston, Texas
Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space